Paragonix to Participate in 23rd Annual Needham Growth Conference in 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today that Bill Edelman, Chief Executive Officer and Chairman of the Board, will present at in the 23^rd Annual Needham Virtual Growth Conference on January 11-15^th, 2021 in a series of virtual 1:1 meetings reviewing the company’s rapid international growth to over 500 heart transplant systems shipped, expanding product portfolio to lung and digital products, and projections for 2021.

For more information contact: https://pgnx.info/38GRy2c

About Paragonix Technologies
Paragonix Technologies designs, produces, and markets organ preservation and transport devices that safeguard organs during the journey between donor and transplant recipient patients. Our award-winning devices mitigate risk in an otherwise high stakes environment by combining best-in class transplant products with a centralized communication and data transfer app to enable better coordination and efficiency during donor organ procurements. Paragonix SherpaPak™ CTS is the only commercially available FDA-cleared and CE-marked preservation and transport device for adult and pediatric donor hearts destined for transplantation. Paragonix is the sole sponsor of GUARDIAN, the largest international clinical data registry on heart preservation, capturing clinical outcome data on Paragonix SherpaPak™ CTS and all other heart preservation technologies. Paragonix’s LUNGguard™ is the only FDA-cleared and CE-marked cold storage preservation and transport device for donor lungs and was commercially launched in the US and in Europe in December 2020. Paragonix is also developing preservation devices for pancreas, kidney and liver — designed to improve donor organ quality and extend donor organ preservation time.

Follow us on Twitter: @ParagonixSherpa
Connect with us on LinkedIn: Paragonix Technologies
Like Us on Facebook: Paragonix SherpaPak